Individual results may vary based on several factors, including severity of disease, initiation of treatment, and duration of therapy.
For the 11,000+ people
who have been treated with
SPINRAZA worldwide,*
victories are personal.
*Based on commercial patients, early access patients, and clinical trial participants through December 2020.
Discover SPINRAZA: the first FDA-approved
treatment for SMA
7+ years
Safety and efficacy
evaluated
in the longest
clinical trial in
SMA to date
3x/year
SPINRAZA is directly delivered to
the central nervous system (CNS)
where
motor neuron loss begins.
After 4
initial loading doses,
SPINRAZA is
given 3 times a year.
From 3 days† to 80 years old‡§
There’s someone from almost every
age group who has been treated
with SPINRAZA.
†Includes clinical trial patients.
‡Clinical studies of SPINRAZA included patients from 3 days
to 16 years of age at first dose, but did not include sufficient numbers of subjects aged 65 and over to determine whether
they respond differently from younger patients.
§Based on commercial patients in the US (including Puerto
Rico) through December 2020.
Safety & side effects
The most common side effects of
SPINRAZA include lower respiratory
infection, fever, constipation, headache,
vomiting, back pain, and post-lumbar
puncture syndrome. These are not all of
the possible side effects of SPINRAZA.
